Download PDF
Thromb Haemost 1998; 79(06): 1130-1135
DOI: 10.1055/s-0037-1615029
Rapid Communication
Schattauer GmbH

Comparison of a Synthetic Antithrombin III-binding Pentasaccharide and Standard Heparin as an Adjunct to Coronary Thrombolysis

Sorin V. Pislaru
1   From the Department of Cardiology, University Hospitals Leuven, Belgium
,
Cristina Pislaru
1   From the Department of Cardiology, University Hospitals Leuven, Belgium
,
Xu Zhu
1   From the Department of Cardiology, University Hospitals Leuven, Belgium
,
Jef Arnout
1   Center for Molecular and Vascular Biology, University of Leuven, Belgium
,
Tony Stassen
1   From the Department of Cardiology, University Hospitals Leuven, Belgium
,
Philippe Vanhove
2   Sanofi Recherche, Toulouse, France
,
Jean-Marc Herbert
2   Sanofi Recherche, Toulouse, France
,
Dirk G. Meuleman
3   Organon International BV, Oss, The Netherlands
,
Frans Van de Werf
1   From the Department of Cardiology, University Hospitals Leuven, Belgium
› Author Affiliations
Further Information

Publication History

Received 02 October 1997

Accepted after revision 06 February 1998

Publication Date:
07 December 2017 (online)

    Permissions and Reprints

Summary

The effects on alteplase-induced thrombolysis of the synthetic ATIII-binding pentasaccharide SR90107A/ORG 31540 (synthetic pentasaccharide, SP) and of standard heparin (SH) were compared in a copper coil model of coronary artery thrombosis in 6 groups of 10 dogs. After 1 h of occlusion, all animals received intravenously alteplase and aspirin, and were randomly assigned to a 2 h infusion of either saline, or one of two doses of SH (100 IU/kg bolus plus 50 IU/kg/h infusion, or 200 IU/kg bolus plus 100 IU/kg/h infusion), or one of three doses of SP (100 nmol/kg bolus plus 50 nmol/kg/h infusion, 200 nmol/kg bolus plus 100 nmol/kg/h infusion, or 400 nmol/kg bolus plus 200 nmol/kg/h infusion). Coronary angiography was performed every 10 min for 4 h. Appropriate doses of SP and SH enhanced alteplase-induced thrombolysis to a similar extent. In contrast, SP was devoid of any anti-IIa activity or aPTT prolongation.

 

  • References

  • 1 Lincoff AM, Topol EJ. Illusion of reperfusion. Does anyone achieve optimal reperfusion during acute myocardial infarction? Circulation 1993; 88: 1361-74.
    PubMedGoogle Scholar
  • 2 Francis CW, Markham REJ, Barlow GH, Florack TM, Dobrzynski DM, Marder VJ. Thrombin activity of fibrin thrombi and soluble plasmic derivatives. J Lab Clin Med 1983; 102: 220-30.
    PubMedGoogle Scholar
  • 3 Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-91.
    CrossrefPubMedGoogle Scholar
  • 4 Eisenberg PR, Miletich JP. Induction of marked thrombin activity by pharmacologic concentrations of plasminogen activators in nonanticoagulated whole blood. Thromb Res 1989; 55: 635-43.
    CrossrefPubMedGoogle Scholar
  • 5 Badimon L, Badimon JJ. Mechanisms of arterial thrombosis in nonparallel streamlines: platelet thrombi grow on the apex of stenotic severely injured vessel wall. Experimental study in the pig model. J Clin Invest 1989; 84: 1134-44.
    CrossrefPubMedGoogle Scholar
  • 6 The GUSTO Investigators.. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-82.
    CrossrefPubMedGoogle Scholar
  • 7 Cercek B, Lew AS, Hod H, Yano J, Reddy NK, Ganz W. Enhancement of thrombolysis with tissue-type plasminogen activator by pretreatment with heparin. Circulation 1986; 74: 583-7.
    CrossrefPubMedGoogle Scholar
  • 8 Stassen JM, Juhan-Vague I, Alessi MC, De Cock F, Collen D. Potentiation by heparin fragments of thrombolysis induced with human tissue-type plasminogen activator or human single-chain urokinase-type plasminogen activator. Thromb Haemost 1987; 58: 947-50.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Rapold HJ, Lu HR, Wu Z, Nijs H, Collen D. Requirement of heparin for arterial and venous thrombolysis with recombinant tissue-type plasminogen activator. Blood 1991; 77: 1020-4.
    PubMedGoogle Scholar
  • 10 Rapold HJ. Promotion of thrombin activity by thrombolytic therapy without simultaneous anticoagulation. Lancet 1990; 335: 481-2.
    PubMedGoogle Scholar
  • 11 Rapold HJ, de Bono DP, Arnold AER, Arnout J, De Cock F, Collen D, Verstraete M. for the European Cooperative Study Group. Plasma fibrino-peptide A levels in patients with acute myocardial infarction treated with alteplase. Correlation with concomitant heparin, coronary artery patency, and recurrent ischemia. Circulation 1992; 85: 928-34.
    CrossrefPubMedGoogle Scholar
  • 12 Tebbe U, Windelar J, Boesl I. et al. Thrombolysis with recombinant unglycosylated single-chain urokinase-type plasminogen activator (saruplase) in acute myocardial infarction: influence of heparin on early patency rate (LIMITS study). Liquemin in myocardial infarction during thrombolysis with saruplase. J Am Coll Cardiol 1995; 26 (02) 365-73.
    CrossrefPubMedGoogle Scholar
  • 13 de Bono DP, Simoons ML, Tijssen J, Arnold AER, Betriu A, Burgersdijk C, Lopez Bescos L, Mueller E, Pfisterer M, Van de Werf F, Zijlstra F, Verstraete M. for the European Cooperative Study Group. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial. Br Heart J 1992; 67: 122-8.
    CrossrefPubMedGoogle Scholar
  • 14 The International Study Group.. In-hospital mortality and clinical course of 20891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet 1990; 336: 71-5.
    CrossrefPubMedGoogle Scholar
  • 15 FTT Collaborative Group.. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311-22.
    PubMedGoogle Scholar
  • 16 Hirsch J. Heparin. N Engl J Med 1991; 324: 1565-74.
    CrossrefPubMedGoogle Scholar
  • 17 Arnout J, Simoons M, de Bono D, Rapold HJ, Collen D, Verstraete M. Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA). J Am Coll Cardiol 1992; 20: 513-9.
    CrossrefPubMedGoogle Scholar
  • 18 Zoldhelyi P, Bichler J, Owen WG, Grill DE, Fuster V, Mruk JS, Chesebro JH. Persistent thrombin generation in humans during specific thrombin inhibition with hirudin. Circulation 1994; 90: 2671-8.
    CrossrefPubMedGoogle Scholar
  • 19 Loscalzo J. Thrombin inhibitors in fibrinolysis. A Hobson’s choice of alternatives. Circulation 1996; 94: 863-5.
    CrossrefPubMedGoogle Scholar
  • 20 Van Amsterdam RGM, Vogel GMT, Visser A, Kop WJ, Buiting MT, Meuleman DG. Synthetic analogues of the antithrombin III-binding pentasaccharide sequence of heparin. Prediction of in vivo residence times. Arterioscler Thromb Vasc Biol 1995; 15: 495-503.
    CrossrefPubMedGoogle Scholar
  • 21 Carrie D, Caranobe C, Saivin S, Houin G, Petitou M, Lormeau JC, Van Boeckel C, Meuleman DG, Boneu B. Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to ATIII in the rabbit: comparison with CY216. Blood 1994; 84 (08) 2571-7.
    PubMedGoogle Scholar
  • 22 Herbert JM, Petitou M, Lormeau JC, Cariou R, Necciari J, Magnani HN, Zandberg P, van Amsterdam RGM, van Boeckel CAA, Meuleman DG. SR 90107A/ORG 31540, a novel anti-factor Xa antithrombotic agent. Cardiovascular Drug Reviews 1997; 15: 1-26.
    CrossrefPubMedGoogle Scholar
  • 23 Denton J, Lane DA, Thunberg L, Slater AM, Lindahl U. Binding of platelet factor 4 to heparin oligosaccharides. Biochem J 1984; 209: 455-60.
    PubMedGoogle Scholar
  • 24 Maccarana M, Lindahl U. Mode of interaction between platelet factor 4 and heparin. Glycobiology 1993; 3: 271-7.
    CrossrefPubMedGoogle Scholar
  • 25 Bernat A, Hoffmann P, Sainte-Marie M, Herbert JM. The synthetic pentasaccharide SR 90107 A/Org 31540 enhances tissue-type plasminogen activator-induced thrombolysis in rabbits. Fibrinolysis 1996; 10 (03) 151-7.
    PubMedGoogle Scholar
  • 26 Eisenberg P, Siegel J, Abendschein DR, Miletich JP. Importance of factor Xa in determining the procoagulant activity of whole-blood clots. J Clin Invest 1993; 91: 1877-83.
    CrossrefPubMedGoogle Scholar
  • 27 Prager NA, Abendschein DR, McKenzie CR, Eisenberg PR. Role of thrombin compared with factor Xa in the procoagulant activity of whole blood clots. Circulation 1995; 92: 962-7.
    CrossrefPubMedGoogle Scholar
  • 28 Vogel GMT, van Amsterdam RGM, Kop WJ, Meuleman DG. Pentasaccha-ride and Orgaran® arrest, whereas heparin delays thrombus formation in a rat arteriovenous shunt. Thromb Haemost 1993; 69: 29-34.
    PubMedGoogle Scholar
  • 29 Boneu B, Necciari J, Cariou R, Sié P, Gabaig AM, Kieffer G, Dickinson J, Lamond G, Moelker H, Mant T, Magnani H. Pharmacokinetics and tolerance of the natural pentasaccharide (SR 90107/ ORG 31540) with high affinity to antithrombin III in man. Thromb Haemost 1995; 74: 1468-73.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Van de Werf F, Bergmann SR, Fox KA, De Geest H, Hoyng CF, Sobel BE, Collen D. Coronary thrombolysis with intravenously administered human tissue-type plasminogen activator produced by recombinant DNA technology. Circulation 1984; 69: 605-10.
    CrossrefPubMedGoogle Scholar
  • 31 The TIMI Study Group.. The thrombolysis in myocardial infarction (TIMI) trial. N Engl J Med 1985; 312: 932-6.
    PubMedGoogle Scholar
  • 32 Jun L, Arnout J, Vanhove P, Dol F, Lormeau JC, Herbert JM, Collen D, Van de Werf F. Comparison of a low-molecular-weight heparin (nadroparin calcium) and unfractionated heparin as adjunct to coronary thrombolysis with alteplase and aspirin in dogs. Coron Artery Dis 1995; 6: 257-63.
    PubMedGoogle Scholar
  • 33 Cadroy Y, Hanson SR, Harker LA. Antithrombotic effects of synthetic pentasaccharide with high affinity for plasma antithrombin III in non-human primates. Thromb Haemost 1993; 70: 631-5.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 34 Collen D, Lu HR, Lijnen HR, Nelles L, Stassen JM. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators. Circulation 1991; 84: 1216-34.
    CrossrefPubMedGoogle Scholar
  • 35 Larsen ML, Abilgaard U, Teien AN, Gjesdal K. Assay of plasma heparin using thrombin and the chromogenic substrate H-D-Phe-Pip-Arg-pNA. Thromb Res 1978; 13: 285-8.
    CrossrefPubMedGoogle Scholar
  • 36 Teien AN, Lie M, Abilgaard U. Assay of heparin in plasma using a chromogenic substrate for activated factor X. Thromb Res 1976; 8: 413-6.
    CrossrefPubMedGoogle Scholar
  • 37 Ravanat C, Freund M, Dol F, Cadroy Y, Roussi J, Incardona F, Maffrand JP, Boneu B, Drouet L, Legrand C. Cross-reactivity of human molecular markers for detection of prothrombotic states in various animal species. Blood Coagul Fibrinolysis 1995; 6: 446-55.
    CrossrefPubMedGoogle Scholar
  • 38 Laird NM, Ware JH. Random-effects models for longitudinal data. Bio-metrics 1982; 38: 963-74.
    CrossrefPubMedGoogle Scholar
  • 39 SAS Institute Inc.. Cary, NC: SAS Institute Inc. SAS Technical Report P-229, SAS/STAT™ Software: Changes and Enhancements, Release 6.07, 1992.
    PubMed
  • 40 Bush LR, Shebuski RJ. In vivo models of arterial thrombosis and thrombolysis. FASEB J 1990; 4: 3087-98.
    CrossrefPubMedGoogle Scholar
  • 41 Collen D, Stump D, Van de Werf F, Jang IK, Nobuhara M, Lijnen HR. Coronary thrombolysis in dogs with intravenously administered human prourokinase. Circulation 1985; 72: 384-8.
    CrossrefPubMedGoogle Scholar
  • 42 Wallach J. Interpretation of diagnostic tests: a handbook synopsis of laboratory medicine. 4th edition. Boston-Toronto: Little, Brown and Company; 1986: 9.
    Google Scholar
  • 43 Topol EJ, George BS, Kereiakes DJ, Stump DC, Candela RJ, Abbottsmith CW, Aronson L, Pickel A, Boswick JM, Lee KL, Ellis SG, Califf RM. TAMI Study Group.. A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. Circulation 1989; 79: 281-6.
    CrossrefPubMedGoogle Scholar
  • 44 Hsia J, Hamilton WP, Kleiman N, Roberts R, Chaitman BR. Ross AM for the Heparin-Aspirin Reperfusion Trial (HART) Investigators. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen-activator for acute myocardial infarction. N Engl J Med 1990; 323: 1433-7.
    CrossrefPubMedGoogle Scholar
  • 45 Bleich SD, Nichols TC, Schumacher RR, Cooke DH, Tate DA, Teichman SL. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 1990; 66: 1412-7.
    CrossrefPubMedGoogle Scholar
  • 46 Sitko GR, Ramjit DR, Stabilito II, Lehman D, Lynch JJ, Vlasuk GP. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis. Circulation 1992; 85: 805-15.
    CrossrefPubMedGoogle Scholar
  • 47 Nicolini FA, Lee P, Malycky JL, Lefkovits J, Kottke-Marchant K, Plow EF, Topol EJ. Selective inhibition of factor Xa during thrombolytic therapy markedly improves coronary artery patency in a canine model of coronary thrombosis. Blood Coag Fibrinol 1996; 7: 39-48.
    CrossrefPubMedGoogle Scholar
  • 48 Lynch Jr. JJ, Sitko GR, Mellott MJ, Nutt EM, Lehman ED, Friedman PA, Dunwiddie CT, Vlasuk GP. Maintenance of canine coronary artery patency following thrombolysis with front-loaded plus low dose maintenance conjunctive therapy. A comparison of factor Xa versus thrombin inhibition. Cardiovasc Res 1994; 28: 78-85.
    CrossrefPubMedGoogle Scholar
  • 49 Visser A, Meuleman DG. Inhibition of the early stages of the thrombin generation reaction by various glycosaminoglycans. Thromb Res 1990; 58: 469-74.
    CrossrefPubMedGoogle Scholar
  • 50 The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994; 90: 1631-7.
    CrossrefPubMedGoogle Scholar
  • 51 Granger CB, Hirsch J, Califf RM, Col J, White HD, Betriu A, Woodlief LH, Lee KL, Bovill EG, Simes RJ, Topol EJ. for the GUSTO investigators. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction. Results from the GUSTO-I trial. Circulation 1996; 93: 870-8.
    CrossrefPubMedGoogle Scholar